Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-β1/ERK1/2 noncanonical pathway

• Main Authors: Xue Liu (Author), Weina Han (Author), Na An (Author), Na Cao (Author), Tingting Wu (Author), Shuang Yang (Author), Lili Ding (Author), Xiaoli Chen (Author), Chao Chen (Author), Aruhan (Author), Yannan Zhang (Author), Kexin Wang (Author), Lianhuan Suo (Author), Jian Huang (Author), Jinhui Wang (Author), Xin Zhao (Author), Jiuxin Zhu (Author), Yan Zhang (Author), Baofeng Yang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cardiac fibrosis is a common pathological manifestation accompanied by various heart diseases, and antifibrotic therapy is an effective strategy to prevent diverse pathological processes of the cardiovascular system. We currently report the pharmacological evaluation of a novel anthraquinone compoun...